Startups
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
Three companies, including two biotech companies and one drug discovery company, announced yesterday the successful closing of Series A financing, with IMIDomics taking the lead.
Biotech company Slingshot Biosciences announced Thursday it had closed a $23 million Series A financing round led by Northpond Ventures.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
More money means more progress for potentially life-saving therapies. Here’s a peek at some biopharma companies adding to their books this week.
Rivus’ CMAs are designed to overcome these illnesses by activating the body’s natural process of mitochondrial uncoupling.
The company’s technology aims to precisely search out genetic mutations at their precise genome location, limiting concerns about toxicities or unwanted cellular changes.
The company launches with the new funding to advance its focus on first-in-class small molecule therapies for neurodegenerative diseases.
Two life sciences companies from two very different areas of medicine announced launches today. Here’s a look.
The first half of 2021 has seen a flurry of IPOs as companies make the move to become publicly traded. The trend continued, as biopharma companies hit the stock exchange this week.
PRESS RELEASES